Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

NCT04709276 is registered in ClinicalTrials.gov with Andrew J. Armstrong, MD as lead sponsor.

NCT NCT04709276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04709276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single Arm Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
Lead sponsor
Andrew J. Armstrong, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 7, 2021
Completion date
August 31, 2028
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, metastatic prostate neuroendocrine carcinoma